GlassScriptPhysician profile
Mark Pequignot
NPI 1770272148
$846.61
in general payments reported to CMS, 2019-2025
15 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $137 · 2024: $330 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $192.24 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $108.21 | 2023-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $106.56 | 2024-2025 | Veozah |
| Abbvie INC. | $98.34 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $71.36 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $62.19 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $39.93 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $34.51 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $29.17 | 2024-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $20.53 | 2025 | |
| Pfizer INC. | $20.53 | 2024 | |
| Axsome Therapeutics, INC. | $18.99 | 2025 | Auvelity |
| Organon LLC | $15.50 | 2023 | Nexplanon |
| Lundbeck LLC | $14.33 | 2025 | Rexulti |
| Tempus Ai, INC | $14.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pequignot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.